British Medical Bulletin Advance Access originally published online on April 1, 2008
British Medical Bulletin 2008 86(1):95-107; doi:10.1093/bmb/ldn014
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Doping in competition or doping in sport?
Sezione di Chimica Clinica, Università di Verona, Italy
Servizio di Immunoematologia e Trasfusione, Azienda Ospedaliera di Verona, Italy
* Correspondence to: Prof. Giuseppe Lippi, Sezione di Chimica Clinica, Dipartimento di Scienze Morfologico-Biomediche, Università degli Studi di Verona, Ospedale Policlinico G.B. Rossi, Piazzale Scuro, 10, 37134 Verona, Italy E-mail: ulippi{at}tin.it or giuseppe.lippi{at}univr.it
Introduction: Since ancient times, competitive athletes have been familiar with the use of ergogenic aids and they will probably continue to use unfair and harmful substances in future, because their inclination to victory, along with the mirage of glory and money, will probably overcome health and legal risks.
Sources of data: We searched PubMed using the term doping over the period 1990 to the present day. We also included non-English journals.
Areas of agreement: By literature searching, it emerges that the phenomenon of doping is complex and multifaceted. It involves a number of causes and factors that do not originate solely in the athletic field, making universality its main feature. It is in fact observed in all ages and levels of competition, and it concerns all sports, even the most unpredictable.
Areas of controversy: The high number of athletes testing positive for anti-doping controls attests that the current strategy might be analytically adequate to unmask most (but not all) doping practices, but it is probably ineffective to prevent athletes to dope and modify this upsetting trend.
Growing points: As doping parallels the use of medications, food supplements, alcohol and social drugs, a reinforced preventive policy is advisable.
Emerging areas for developing research: The current anti-doping policy should be replaced with a more efficient and practical strategy to identify and monitor abnormal and harmful deviations of the biochemical and haematological profiles.
Keywords: anti-doping • doping • ergogenic aids • sports
Accepted for publication March 16, 2008.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  P. J. Ambrose, C. Tsourounis, R. Olander, and F. Uryasz Characteristics of Drug and Dietary Supplement Inquiries by College Athletes Sports Health: A Multidisciplinary Approach, January 1, 2010; 2(1): 12 - 18. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A Petroczi and D P Naughton Popular drugs in sport: descriptive analysis of the enquiries made via the Drug Information Database (DID) Br. J. Sports Med., October 1, 2009; 43(11): 811 - 817. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Lippi, U. G. Longo, and N. Maffulli Genetics and sports Br. Med. Bull., February 9, 2009; (2009) ldp007v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Lippi, W. E. Jelkmann, G. L. Salvagno, G. C. Guidi, C. R. Valeri, G. Ragno, B. Kayser, F. Lasne, Y. O. Schumacher, T. Pottgiesser, et al. Comments on Lundby et al.'s "testing for recombinant human erythropoietin in urine: problems associated with current anti-doping testing". Problems associated with current anti-doping testing: is quality assessment a reliable solution? J Appl Physiol, December 1, 2008; 105(6): 1992 - 1993. [Full Text] [PDF]
|
|